The Clinical Effects of Laser Acupuncture on Hospitalized Patients With Severe COVID-19: A Randomized Clinical Trial

被引:0
|
作者
Shojaeddin, Arista [1 ]
Fatemi, Alireza [2 ]
Razzaghi, Zahra [1 ]
Pishgahi, Mehdi [3 ]
Sherafat, Somayeh Jahani [1 ]
Razzaghi, Mohammadreza [1 ]
Shahrzad, Mohamad Karim [4 ]
Anaraki, Nafiseh [4 ]
Salehi, Chiman [4 ]
Amiri, Aslan [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Cardiol Dept, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Internal Med & Endocrinol Dept, Tehran, Iran
关键词
Laser acupuncture; Laser therapy; COVID-19; Severity; THERAPY LLLT; PAIN; IRRADIATION; IL-1-BETA; RELEVANCE; ASTHMA; BLIND; LUNG; ACTS;
D O I
10.34172/jlms.2023.14
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: The coronavirus disease (COVID-19) was extended to the entire population in China and around the world, and its mortality rate was about 3.4%. The impact of laser therapy on chronic respiratory diseases has been shown in previous studies. This study was aimed at examining the effects of laser acupuncture (LA) on patients with severe COVID-19. Methods: In the present study, 60 patients with a positive reverse transcription-polymerase chain reaction (RT-PCR) test were assigned to the intervention and control groups (30 patients in each group). The intervention group was treated with LA, that is, laser light with low energy on acupuncture points, once a day for five consecutive days. Results: The participants' mean age in the intervention and control groups was 48.96 +/- 12.65 and 53.16 +/- 12.28 respectively; 70% of the patients were male and 30% of them were female. IL6 had a significant reduction in the intervention group (P value = 0.038) in comparison with the control group (P value = 0.535). Furthermore, the mean admission time in the control group was significantly higher than that in the intervention group (P value = 0.047). However, the mortality rate in the intervention group was zero, but three patients in the control group died. Conclusion: Our study showed that LA can be used as supportive therapy for routine treatment in patients with severe COVID-19. Moreover, due to LA safety and it's low cost, it could be recommended as an adjuvant to conventional therapy in patients interested in treating their disease with such a method.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Clinical outcomes in cancer patients hospitalized with COVID-19
    Zylberman, Marcelo
    Diaz-Couselo, Fernando A.
    Irrazabal, Celica
    Flagel, Santiago
    Custidiano, Rosario
    Racciopi, Agustina
    Nicolini, Carla
    Bachetti, Pierina
    Rebora, Juan
    Manzano, Natalia
    Tavella, Margarita
    Valle, Sandra
    Noro, Laura
    Halac, Sebastian
    Cassal, Eric
    Paganini, Lisandro
    Aguirre, Marina
    Dictar, Miguel
    MEDICINA-BUENOS AIRES, 2021, 81 (05) : 695 - 702
  • [32] Evaluation of the Efficacy of Arbidol in Comparison with the Standard Treatment Regimen of Hospitalized Patients with Covid-19: A Randomized Clinical Trial
    Yadegarinia, Davood
    Tehrani, Shabnam
    Abolghasemi, Sara
    Zarghi, Afshin
    Sali, Shahnaz
    Zolfaghari, Farnaz
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2020, 15 (05): : 1 - 6
  • [33] Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial
    Siami, Zeinab
    Aghajanian, Sepehr
    Mansouri, Somayeh
    Mokhames, Zakiye
    Pakzad, Reza
    Kabir, Kourosh
    Norouzi, Mehdi
    Soleimani, Alireza
    Yaghoobi, Mojtaba Hedayat
    Shadabi, Shahrzad
    Tajbakhsh, Ramin
    Kheirabad, Ali Kargar
    Mozhgani, Sayed-Hamidreza
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 108 : 306 - 308
  • [34] Clinical analysis of severe COVID-19 patients
    Wang, Hao
    Sun, Bin
    Li, Xiayuan
    Wang, Yun
    Yang, Zhengping
    TECHNOLOGY AND HEALTH CARE, 2022, 30 : S225 - S234
  • [35] Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients-Randomized Controlled Trial
    Domazet Bugarin, Josipa
    Dosenovic, Svjetlana
    Ilic, Darko
    Delic, Nikola
    Saric, Ivana
    Ugrina, Ivo
    Stojanovic Stipic, Sanda
    Duplancic, Bozidar
    Saric, Lenko
    NUTRIENTS, 2023, 15 (05)
  • [36] Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19
    Walter Ageno
    Chiara Cogliati
    Martina Perego
    Domenico Girelli
    Ernesto Crisafulli
    Francesca Pizzolo
    Oliviero Olivieri
    Marco Cattaneo
    Alberto Benetti
    Elena Corradini
    Lorenza Bertù
    Antonello Pietrangelo
    Internal and Emergency Medicine, 2021, 16 : 989 - 996
  • [37] Efficacy and Safety of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial
    Siami, Zeinab
    Dehghan, Danial
    Khavandegar, Armin
    Lak, Mehran
    Bakhtiyari, Mahmood
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2022, 24 (05)
  • [38] Clinical profiles and mortality predictors of hospitalized patients with COVID-19 in Ethiopia
    Abera, Eyob Girma
    Tukeni, Kedir Negesso
    Chala, Temesgen Kabeta
    Yilma, Daniel
    Gudina, Esayas Kebede
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [39] Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
    Rahmani, Hamid
    Davoudi-Monfared, Effat
    Nourian, Anahid
    Khalili, Hossein
    Hajizadeh, Nooshin
    Jalalabadi, Narjes Zarei
    Fazeli, Mohammad Reza
    Ghazaeian, Monireh
    Yekaninejad, Mir Saeed
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 88
  • [40] Clinical characteristics of Japanese patients with moderate to severe COVID-19
    Otoshi, Ryota
    Hagiwara, Eri
    Kitayama, Takaaki
    Yamaya, Takafumi
    Higa, Katsuyuki
    Murohashi, Kota
    Sato, Yozo
    Tabata, Erina
    Shintani, Ryota
    Okabayashi, Hiroko
    Ikeda, Satoshi
    Niwa, Takashi
    Nakazawa, Atsuhito
    Oda, Tsuneyuki
    Okuda, Ryo
    Sekine, Akiamasa
    Kitamura, Hideya
    Baba, Tomohisa
    Komatsu, Shigeru
    Ogura, Takashi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (06) : 895 - 901